Skip to main content
. 2022 Sep 14;13:949669. doi: 10.3389/fneur.2022.949669

Figure 1.

Figure 1

Flow of patients in our study. ar-tPA: recombinant tissue plasminogen activator. bThrombolysis-only group for patients with intravenous thrombolysis and without endovascular therapy; EVT group for patients with endovascular therapy and with/without intravenous thrombolysis. cExcluded from Cox proportional hazards models because of missing data on patient-level characteristics and follow-up times.